In vitro release of corticosteroids in a new model of slow release platform in the treatment of osteoarthritis. S. Colen, M. van Rijen, S. Plomp, L. Creemers Osteoarthritis and Cartilage Volume 22, Pages S389-S390 (April 2014) DOI: 10.1016/j.joca.2014.02.727 Copyright © 2014 Terms and Conditions
Table 1: PGE2-levels of all situations compared to PGE2-levels of chondrocytes treated with TNF-alpha Osteoarthritis and Cartilage 2014 22, S389-S390DOI: (10.1016/j.joca.2014.02.727) Copyright © 2014 Terms and Conditions
Table 2: PGE2-levels after TNF-alpha + TA -7 and MS -7 compared to PGE2-levels after TNF-alpha Osteoarthritis and Cartilage 2014 22, S389-S390DOI: (10.1016/j.joca.2014.02.727) Copyright © 2014 Terms and Conditions
Table 3: PGE2-levels of negative control and no TNF-alpha and empty MS compared to PGE2-levels of chondrocytes treated with TNF-alpha Osteoarthritis and Cartilage 2014 22, S389-S390DOI: (10.1016/j.joca.2014.02.727) Copyright © 2014 Terms and Conditions
Table 4: PGE2-levels of chondrocytes treated with TNF-alpha and MS compared to PGE2-levels of chondrocytes treated with TNF-alpha Osteoarthritis and Cartilage 2014 22, S389-S390DOI: (10.1016/j.joca.2014.02.727) Copyright © 2014 Terms and Conditions